论文部分内容阅读
目的：为了了解ｐ５３，ｃｆｏｓ及ｃＡｂｌ三种癌基因产物在骨巨细胞瘤中的表达情况，探讨基因改变与骨巨细胞瘤复发、恶变等生物学行为间的关系．方法：采用免疫细胞化学方法对９８例存档骨巨细胞瘤标本进行了检测．结果：①ｐ５３，ｃｆｏｓ和ｃＡｂｌ三种癌基因产物在骨巨细胞瘤组织中均有表达，阳性率分别为３９８％，４９０％及７５５％．阳性细胞散在或呈片状、团块状分布．本组病例中，全部阴性者１２例（１２２％），全部阳性者２１例（２１４％），仅ｐ５３阳性者７例（７１％），仅ｃｆｏｓ阳性者１例（１０％），仅ｃＡｂｌ阳性者２８例（２８６％），ｐ５３和ｃｆｏｓ阳性者２例（２０％），ｐ５３和ｃＡｂｌ阳性者８例（８１％），ｃｆｏｓ和ｃＡｂｌ阳性者２６例（２６５％）．②三种癌基因产物在骨巨细胞瘤Ⅰ，Ⅱ，Ⅲ级三组不同组织分级中均有表达，ｐ５３和ｃｆｏｓ三组间无显著性差异；而ｃＡｂｌ在Ⅱ级与Ⅲ级间有显著性差异（Ｐ＜００５）．③三种癌基因产物阳性表达在骨巨细胞瘤有、无复发组之间，有、无局部侵袭或（和）转移组之间，均无显著性意义．④ｐ５３与ｃｆｏｓ之间阳性率无显著性意义（Ｐ＞００５），而ｃＡｂｌ?
Objective: To investigate the expression of three oncogenes p53, cfos and cAbl in giant cell tumor of bone, to explore the relationship between gene alterations and biological behaviors such as recurrence and malignancy of giant cell tumor of bone. METHODS: Immunohistochemistry was used to detect 98 cases of giant cell tumor of bone graft. RESULTS: The three oncogene products of p53, cfos and cAbl were all expressed in giant cell tumors of bone, the positive rates were 39.8%, 49.0% and 75.5%, respectively. Positive cells scattered or flaky, lumps distributed. In this group of cases, all were negative in 12 cases (12. 2%), all positive in 21 cases (21.4%), and only p53 positive in 7 cases (7.1%), only c-fos positive in 1 case. (10%), only 28 patients with c-Abl positive (286%), 2 patients with p53 and cfos positive (20%), 8 patients with p53 and cAbl positive (8) 1%), cfos and cAbl positive in 26 cases (265%). 2 The three oncogene products were expressed in different tissues and grades of giant cell tumor of bone type I, II, and III. There was no significant difference between p53 and cfos, while cAbl was in grades II and III. There was a significant difference between them (P<005). 3The positive expression of the three oncogene products was not significant between the presence and absence of recurrence in giant cell tumors of bone, with or without local invasion or (and) metastasis. The positive rate between 4p53 and cfos was not significant (P>005), but cAbl?